Giving Compass' Take:

•  Countries are investing more money in global health causes, mainly, in order to battle the world's deadliest diseases. 

• Will we see this investment continue to increase as more blended financing models become relevant for supporting global health initiatives? 

• Read more about innovative financing for global health problems. 

The funding that the world invests in tackling 33 of the deadliest diseases is at its highest level since records began 11 years ago. Over $3.5 billion (about £2.8 billion) was spent on detecting, treating, and preventing neglected diseases like tuberculosis, malaria, and HIV/AIDS in 2017, according to a report published this month. That marks a 7% funding increase compared to 2016.

“This was the largest increase in both relative and absolute terms since 2008, and the first time since 2009 that there has been two consecutive years of growth in global funding for neglected diseases R&D,” reads the “G-Finder” report, which is published every year by an Australian nonprofit called Policy Cures Research on behalf of the Gates Foundation.

Of all the neglected diseases featured in the report, HIV/AIDS, TB, and malaria between them received more then two-thirds of the overall global investment.

As we head into a year that will be crucial for global health investment, however, there is a lot more work to do and a lot more funders who need to be contributing — with the report noting that funding still relies too much on a few big investors.

The US and the UK are the biggest investors in global health, according to the report — with the US providing 39% of the total through its National Institutes of Health, reported the BBC. Meanwhile, the UK, the European Commission, Germany, and India are all noted as having increased their investment.

But no one is yet hitting that target. The United States is closest, followed by the UK, but no other country is even half way towards hitting the guideline spend laid out by the WHO.

Read the full article about global health investment by Imogen Calderwood at Global Citizen